| abstract |
The present invention provides a compound as defined by the formula (I) or a pharmaceutically acceptable salt thereof.n n n Formula In n n n n n n n Wherein R 1 , Q, S, T, U, V and R 2 are as defined in the specification.n n n The present invention also provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, mixed with a pharmaceutically acceptable carrier, excipient or diluent as defined herein. The present invention also provides a method of inhibiting MMP-13 enzyme in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present invention also provides a method of treating a disease mediated by MMP-13 enzyme in a patient, comprising administering to the patient a compound of formula (I) or a pharmaceutically acceptable salt thereof, alone or in a pharmaceutical composition. . In addition, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof alone or in a pharmaceutical composition with heart disease, multiple sclerosis, osteoarthritis, rheumatoid arthritis, arthritis other than the osteoarthritis and rheumatoid arthritis, heart deficiency, inflammation Providing a method of treating said disease in said patient, comprising administering to a patient suffering from diseases such as enteric disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal disease, psoriasis, atherosclerosis, and osteoporosis do. The present invention also provides combinations comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with other pharmaceutically active ingredients as described herein. |